Trial Profile
Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Quercetin (Primary)
- Indications Transplant rejection
- Focus Pharmacodynamics; Proof of concept
- Acronyms HTSS
- 14 Sep 2023 Planned primary completion date changed from 15 Oct 2023 to 15 Oct 2024.
- 19 Jan 2023 Planned End Date changed from 31 Dec 2023 to 15 Oct 2024.
- 19 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 15 Oct 2023.